Vitamin K2 (MK-7).

Vitamin D3 raises calcium absorption and drives production of osteocalcin and matrix Gla protein, and MK-7 supplies the carboxylation step those proteins need to bind calcium. The two act on opposite ends of the same calcium-handling pathway, which is why they are formulated together.

Carboxylated osteocalcin is the protein that binds calcium into the bone matrix, and MK-7 is the cofactor for that carboxylation. Calcium supplies the mineral and MK-7 supports where the body directs it.

Magnesium is the cofactor for the hydroxylases that activate vitamin D, and active vitamin D drives the Gla protein expression MK-7 carboxylates. It sits upstream on the same sequence rather than duplicating any step.

MK-7 is one menaquinone among several, and it differs from MK-4 mainly in side-chain length, lipoprotein binding and half-life. Formulas often pair the fast-acting MK-4 with the persistent MK-7.

Phylloquinone is taken up mostly by liver and cleared in hours, while MK-7 stays in circulation for days and reaches bone and vessel wall. Carrying both covers the full spread of vitamin K-dependent carboxylation.

MK-7 acts through the identical carboxylase and epoxide reductase cycle that defines vitamin K activity. Total intake across vitamers is what the cycle sees.

High alpha-tocopherol intakes interfere with menaquinone absorption and with the carboxylase cycle, which adds to effects on normal clotting. It is a genuine dose-dependent anti-synergy worth stating.

MK-7 is more lipophilic than phylloquinone and depends on bile salts and dietary fat for micellar uptake. An oil base raises the absorbed fraction and is standard in MK-7 softgels.

Vitamin D raises calcium absorption and induces osteocalcin and matrix Gla protein, and MK-7 supplies the carboxylation that lets those proteins bind calcium. The pairing is the most common reason MK-7 appears in a formula at all.

Menaquinone-7 and ubiquinone are both quinones carrying a long polyisoprenoid tail assembled from the same prenyl pyrophosphate pool. That shared chemistry is why the two behave alike in a softgel: both partition into the oil phase and both travel on lipoproteins after a meal containing fat. The overlap is structural and pharmacokinetic, not a demonstrated combined clinical effect.

Natto fermentation produces menaquinone-7 and the fibrinolytic enzyme nattokinase in the same broth, which is why the two appear together in products built on a natto platform. The link is provenance rather than a measured interaction between them. Anyone using either alongside blood-thinning medication should be under clinician supervision, since vitamin K and fibrinolytic enzymes act on opposite sides of clot chemistry.

Menaquinone-7 is strongly lipophilic and reaches the enterocyte only after bile salts and phospholipids emulsify it into mixed micelles. Lecithin supplies phosphatidylcholine that participates in that micellar phase, which is why powdered vitamin K preparations are often co-formulated with it. The effect is on delivery, not on vitamin K activity itself.

Phosphatidylcholine is the phospholipid that carries fat-soluble vitamins through the mixed-micelle step and into chylomicrons. Menaquinone-7 then circulates on triglyceride-rich lipoproteins, which is one reason its plasma residence is longer than that of shorter-chain menaquinones. This is delivery chemistry and says nothing about a joint clinical outcome.

Krill oil carries a large phospholipid fraction alongside its fatty acids, so it provides both the fat and the emulsifier that menaquinone-7 absorption depends on. Formulators use it as a single-ingredient carrier. The rationale is absorption chemistry rather than a measured combination.

Retinol and menaquinone-7 both depend on bile salt micelles and overlapping enterocyte lipid transporters, so very large doses of one fat-soluble vitamin can reduce the uptake of another taken at the same moment. At the amounts used in ordinary multivitamins this competition is generally minor. It is worth knowing when a high-dose retinol product and a vitamin K product are taken with the same meal.

Colonic bacteria produce a mixture of menaquinones, and part of the body's vitamin K pool has microbial origin. How much of that colonic menaquinone is actually absorbed remains uncertain, because the colon has little bile salt and limited lipid absorption capacity. Regard the pairing as mechanistic support for the endogenous pool, not a substitute for the ingested vitamin.

Several lactic acid bacteria generate menaquinones during fermentation, which is why fermented dairy and vegetable foods carry measurable vitamin K2. In a supplement the contribution from a live culture is far smaller than the dose in the capsule. The row records a real biosynthetic capability rather than a clinical additive effect.

Fermentable fibre feeds the colonic community that produces menaquinones, so a prebiotic can change the composition of that endogenous pool. The size of the change in circulating vitamin K status has not been established. Read this as a plausible modulating link rather than a measured one.

Menaquinone-7 supports the carboxylation of osteocalcin, a bone matrix protein, while boron is studied in the handling of calcium and magnesium in bone tissue. The two are frequently combined in bone formulas on that reasoning. No combination trial supports a joint effect, so the confidence stays low.

Strontium incorporates into the hydroxyapatite lattice in place of calcium, and it also inflates bone densitometry readings because it is denser than calcium. Menaquinone-7 acts earlier in the sequence, on the carboxylation of matrix proteins. Anyone combining them should know the density reading is a marker distorted by strontium, not an outcome.

Alkaline phosphatase is a zinc metalloenzyme active in mineralising tissue, and osteocalcin carboxylation by vitamin K happens in the same osteoblast. The two nutrients touch different steps of one process. The link is cofactor biochemistry, not a trial of the combination.